Nutriband Inc. (FRA:9WV)
Germany
· Delayed Price · Currency is EUR 4.040
+0.420 (11.60%)
At close: Dec 5, 2025
Nutriband Company Description
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States.
The company’s lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.
It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products.
The company has commercial development and clinical supply agreement with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Nutriband Inc.
| Country | United States |
| Founded | 2016 |
| Industry | Pharmaceutical Preparations |
| CEO | Gareth Sheridan |
Contact Details
Address: 121 South Orange Avenue Orlando, Nevada 32801 United States | |
| Phone | 407 377 6695 |
| Website | nutriband.com |
Stock Details
| Ticker Symbol | 9WV |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | February - January |
| Reporting Currency | USD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gareth Sheridan | Chief Executive Officer |
| Gerald Goodman | Chief Financial Officer |
| Alan Smith | Chief Operating Officer |